- First Online:
▴ Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance.
▴ In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or dyslipidaemia, oral rimonabant 20mg once daily reduced weight and waist circumference to a significantly greater extent than placebo.
▴ A significantly greater proportion of rimonabant than placebo recipients achieved the clinically significant weight-loss target of ≥5% or ≥10% of initial weight.
▴ Rimonabant was associated with significant improvements in glycaemic control relative to placebo, with ≈57% of the reduction in glycosylated haemoglobin being independent of the effects of weight loss in one trial.
▴ Improvements in other cardiometabolic risk factors (i.e. increases in high-density lipoprotein-cholesterol [HDL-C] and decreases in triglyceride [TG] levels) were significantly greater with rimonabant than with placebo.
▴ The improvement in lipid profile also demonstrated a weight-independent effect, with ≈47–58% of the mprovement in HDL-C and TG being beyond that expected through weight loss alone.
▴ Rimonabant was generally well tolerated, with most adverse events considered mild to moderate in severity.
- 1.World Health Organization. Obesity and overweight. 2006 [online]. Available from URL: http://www.who.int/ [Accessed 2006 Jul]
- 2.National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication No. 98-4083 [online]. Available from URL: http://www.nhlbi.nih.gov [Accessed 2006 Jun 25]
- 14.Data on file, Sanofi-Aventis, 2006Google Scholar
- 29.Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, aCBl receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003 Feb; 284(2): R345–53Google Scholar
- 30.Acomplia: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/ [Accessed 2006 Jul 20]
- 35.Kanamaluru V, Lockwood G, Bonnet D, et al. Lack of effect of rimonabant on the pharmacokinetics of digoxin [abstract]. J Clin Pharmacol 2005; 45(9): 1081Google Scholar
- 36.Kanamaluru V, Lockwood G, Bonnet D, et al. Lack of effect of rimonabant on the pharmacokinetics of oral contraceptives [abstract]. J Clin Pharmacol 2005; 45(9): 1082Google Scholar
- 37.Grandison M, Kanamaluru V, Lockwood G, et al. Lack of effect of rimonabant on the pharmacokinetics and pharmacodynamics of warfarin [abstract]. J Clin Pharmacol 2005; 45(9): 1082Google Scholar
- 38.Grandison M, Kanamaluru V, Lockwood G, et al. Lack of effect of rimonabant on the pharmacokinetics and pharmacodynamics of midazolam [abstract]. J Clin Pharmacol 2005; 45(9): 1082Google Scholar
- 39.Van Gaal L. Rio-Europe: 2 year results [oral presentation]. 54th Annual Scientific Session of the American College of Cardiology; 2005 Mar 6–9; Orlando (FL)Google Scholar
- 42.Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. Epub 2006 Oct 27Google Scholar
- 44.Van Gaal L, Scheen A, Despres J-P, et al. Effect of rimonabant on systolic and diastolic blood pressure in overweight/obese patients with/without co-morbidities [abstract]. The 16th Scientific Meeting of the European Society of Hypertension; 2006 Jun 12–15; MadridGoogle Scholar